This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 2042466 results found since Jan 2013.
Needs and Preferences of Patients With Head-neck Cutaneous SCC
Conditions: Cutaneous Squamous Cell Carcinoma; Cutaneous Squamous Cell Carcinoma of the Head and Neck; Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck; Squamous Cell Carcinoma of the Head and Neck; Skin Cancer; Patient Satisfaction; High-Risk Cance r; Preference, Patient; Decision Making; Interview Intervention: Other: Regular care with additional administration of a semi-structured interview Sponsor: Maastricht University Medical Center Active, not recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer Intervention: Drug: PLB1004 Sponsor: Avistone Biotechnology Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma
Conditions: Head Neck; Squamous Cell Carcinoma of Head and Neck Interventions: Drug: Pembrolizumab; Drug: Magrolimab; Drug: cetuximab; Drug: Docetaxel Sponsors: M.D. Anderson Cancer Center; Gilead Sciences Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies
Conditions: Lymphoma, Non-Hodgkin; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Lymphoma, B-Cell Intervention: Drug: ALETA-001 Sponsors: Cancer Research UK; Aleta BioTherapeutics Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance
Condition: Advanced Non-small Cell Lung Cancer Intervention: Drug: almonertinib Sponsor: Qianfoshan Hospital Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
First-In-Human Study of STX-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations
Conditions: Non-Small Cell Lung Cancer; NSCLC; EGFR/HER2 Exon 20 Insertion Mutation Intervention: Drug: STX-721 Sponsor: Scorpion Therapeutics, Inc. Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Study of HS-10516 in Patients With Advanced Clear Cell Renal Cell Carcinoma
Condition: Renal Cell Carcinoma Intervention: Drug: HS-10516 Sponsor: Jiangsu Hansoh Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Pancreatic, Colorectal and Non-Small Cell Lung Cancers With KRAS G12V Mutations
Conditions: Metastatic Colorectal Adenocarcinoma; Metastatic Lung Non-Small Cell Carcinoma; Metastatic Pancreatic Adenocarcinoma; Stage IV Colorectal Cancer AJCC v8; Stage IV Lung Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8 Interventions: Drug: Bendamustine; Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Drug: Cyclophosphamide; Procedure: Echocardiography; Drug: Fludarabine; Procedure: Leukapheresis; Procedure: Magnetic Resonance Imaging; Procedure: M ultigated Acquisition Scan; Procedure:...
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma
Condition: Esophageal Squamous Cell Carcinoma Interventions: Drug: Carrelizumab; Drug: Paclitaxel injection; Drug: Cisplatin; Radiation: Concurrent chemoradiotherapy Sponsor: The First Affiliated Hospital with Nanjing Medical University Enrolling by invitation
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer
Condition: Neoplasms Interventions: Drug: GSK3901961; Drug: Cyclophosphamide; Drug: Fludarabine Sponsor: GlaxoSmithKline Terminated
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody
Conditions: Lung Cancer; TKI Resistance; EGFR Sensitive Mutation; Anlotinib; Pianzumab Interventions: Drug: Anlotinib; Drug: Penpulimab Sponsors: Degan Lu; Wu Jieping Medical Foundation Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer
Conditions: Advanced Solid Tumor; Refractory Tumor Interventions: Radiation: Radiotherapy; Drug: PD-1/PD-L1 inhibitor; Drug: Granulocyte-macrophage colony-stimulating factor subcutaneous injection; Drug: Interleukin 2 subcutaneous injection; Drug: Endostatin Sponsor: Second Affiliated Hospital of Soochow University Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Conditions: NAFLD; MASLD; Mild Inflammatory Context Intervention: Dietary Supplement: TOTUM-448 Sponsors: Valbiotis; Clinic'n'Cell; University Hospital, Clermont-Ferrand Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
Phase I Clinical Trial of RC19D2 Cell Injection in the Treatment of Diffuse Large B-cell Lymphoma
Conditions: Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-cell Lymphoma Intervention: Biological: RC19D2 cell injection Sponsor: Beijing Yongtai Ruike Biotechnology Company Ltd Recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
Condition: Large B-Cell Lymphoma Interventions: Drug: Glofitamab; Drug: Polatuzumab vedotin; Drug: Rituximab; Drug: Cyclophosphamide; Drug: Doxorubicin; Drug: Prednisone Sponsor: Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - September 21, 2023 Category: Research Source Type: clinical trials